Coriell Life Sciences (CLS) is at the forefront of precision medicine, leveraging genetic science to enhance medical care and promote healthier outcomes. The company specializes in pharmacogenomics, which examines how an individual's genetic makeup influences their response to medications. This approach aims to eliminate the trial-and-error method of prescribing, ensuring that patients receive medications that are both safe and effective for their unique genetic profiles. CLS's Corigen® program exemplifies this commitment by providing a population-scale Medication Safety Program that utilizes DNA testing to improve medication efficacy and reduce healthcare costs.

In addition to pharmacogenomics, Coriell Life Sciences is actively involved in research analysis across various health domains, including women's health, urinary tract infections, respiratory pathogens, and soft tissue wound healing. By integrating genetic testing into these areas, CLS seeks to develop tailored diagnosis and treatment plans that cater specifically to individual patient needs. The company's partnerships with healthcare organizations, academic institutions, and laboratories further enhance its ability to deliver innovative solutions and drive the adoption of precision medicine as a new standard of care.

United States

Coriell Life Sciences (CLS), an international leader in precision medicine, delivers DNA testing benefits that empower the most precise medical care, improve population health, and reduce healthcare costs. We work with retirement systems, pension funds, health plans, employers, public and private organizations, pharmacy benefit managers (PBMs), benefits brokers, and laboratories around the globe to eliminate needless risks, costs, and waste associated with trial-and-error prescribing. 

https://www.youtube.com/c/CoriellLifeSciences

Coriell Life Science

Company Details